Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical failure · children under 18 years of age with enteric fever
Ceftriaxone showed no clear difference in clinical failure compared with azithromycin (low certainty).
1 finding from 1 review
Microbiological failure · children under 18 years of age with enteric fever
It is very uncertain whether ceftriaxone changes microbiological failure compared with azithromycin (very low certainty).
1 finding from 1 review
All‐cause mortality · people with cancer who have febrile neutropenia
Pre‐emptive antifungal therapy showed no clear difference in all‐cause mortality compared with empirical antifungal therapy (low certainty).
1 finding from 1 review
Mortality ascribed to fungal infection · people with cancer who have febrile neutropenia
Pre‐emptive antifungal therapy showed no clear difference in mortality ascribed to fungal infection compared with empirical antifungal therapy (low certainty).
1 finding from 1 review
Proportion of antifungal agent use (other than prophylactic use) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes proportion of antifungal agent use (other than prophylactic use) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Duration of antifungal use (days) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes duration of antifungal use (days) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Invasive fungal infection detection · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes invasive fungal infection detection compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Adverse effects · people with cancer who have febrile neutropenia
1 finding from 1 review
Total VTE · people undergoing bariatric surgery
Higher‐dose heparin showed no clear difference in VTE compared with standard‐dose heparin (low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
VTE‐related mortality4 · people undergoing bariatric surgery
1 finding from 1 review
PE · people undergoing bariatric surgery
1 finding from 1 review
Deep vein thrombosis · people undergoing bariatric surgery
Heparin showed no clear difference in DVT compared with pentasaccharide (low certainty).
1 finding from 1 review
Thrombocytopenia · people undergoing bariatric surgery
It is very uncertain whether heparin changes adverse events (thrombocytopenia) compared with pentasaccharide (very low certainty).
1 finding from 1 review
Total VTE · people undergoing bariatric surgery
Heparin started before showed no clear difference in VTE compared with after the surgical procedure (low certainty).
1 finding from 1 review
Major bleeding · people undergoing bariatric surgery
It is very uncertain whether heparin started before changes major bleeding compared with after the surgical procedure (very low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
VTE‐related mortality4 · people undergoing bariatric surgery
1 finding from 1 review
PE · people undergoing bariatric surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found